ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0265

In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases

Nicolai Leuchten, Christoph Weinert and Martin Aringer, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany

Meeting: ACR Convergence 2022

Keywords: Decision analysis, Disease Activity, Musculoskeletal Examination, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Disease activity scores like CDAI, SDAI, or DAS28, are essential for measuring rheumatoid arthritis (RA) disease activity. These scores do not contain foot joints. However, foot pain is an important aspect of morbidity for RA patients, which leads to reduced mobility and quality of life.

Methods: Joint scores of 545 RA outpatients, performed at each visit, were followed 08/2004 – 12/2020. Informed consent was obtained from every patient.

The standard CDAI cut-offs used were CDAI ≤ 2.8 for remission (REM), >2.8 – 10.0 for low disease activity (LDA), >10.0 – 22.0 for moderate disease activity (MDA) and >22.0 for high disease activity (HDA).
Active foot joint involvement (FJI) was defined as having at least one swollen (SJ) or tender (TJ) foot joint in patients who ever had palpable synovitis in any of these joints. The visits were grouped according to the number of total swollen joints (SJ 0-28). The mean Physician Global Assessment of disease activity (PhGA) was calculated for each SJ group and the difference between the mean PhGA in patients with and without FJI was calculated for each SJ group (ΔPhGA).

Results: A total of 7,577 visits of 545 patients were included, for a mean of 14 visits per patient. 413 (75.8%) of the patients were female, the mean age at visit was 59 years, mean disease duration was 13 years, 284 (52.1%) were ACPA positive. The median CDAI at visit was 4.3 (interquartile range IQR 1.6 – 9.0), the median DAS28 was 2.56 (IQR 1.89 – 3.37), the median CRP was 2.5 (IQR 1.0 – 6.2) mg/L.

At 2,853 (37.7%) visits the patient was in REM, at 3,134 (41.4%) visits in LDA, at 1,265 (16.7%) visits in MDA and at 324 (4.3%) visits in HDA.

Patients with FJI were more active and scored higher on CDAI (9.1 vs. 3.4, p< 0.001) and DAS28 (3.19 vs. 2.45, p< 0.001), even though these indices do not include the foot joints. This was mainly due to higher patient global assessment of disease activity (3.1 vs. 2.0, p< 0.001).

Involvement of the feet also led to a higher physician estimate of global disease activity. The mean difference of PhGA between patients with and without involvement of their feet (ΔPhGA) was meaningful for joint counts 0- 10, with an unweighted mean ΔPhGA of 0.273.
Of the 217 patients with FJI, 3,776 visits were analyzed. For patients with FJI, the potential change in disease activity was calculated by subtracting ΔPhGA from the CDAI at each visit. For 3,662 (97.0%) of the visits, this did not result in a change of disease activity state. For 90 (2.4%) visits, disease activity changed from LDA to REM, for 21 (0.6%) from MDA to LDA, and for only 3 (0.1%) visits from HDA to MDA.
At 83 (1.1%) visits of a total of 59 (10.8%) patients, only swollen foot joints without tender foot joints were recorded.

Conclusion: Patients with foot involvement are more active and score disproportionally high on disease activity indices, even though these do not include foot joints.
While patients suffer significantly from foot involvement, underestimating disease activity by not assessing the feet would have changed the disease activity state for 3.1% of the visits only.

Palpable synovitis without tenderness, which would be missed by performing only a metatarsophalangeal squeeze test, was found at one in a hundred visits.

Supporting image 1

Change in CDAI disease activity state in patients with FJI when ΔPhDA is subtracted from CDAI. (LDA: low, MDA: moderate, HDA: high disease activity).

Supporting image 2

Difference of mean Physician Global Disease Activity (PhDA) in patients with/without foot involvement per joint count (ΔPhDA).


Disclosures: N. Leuchten, Roche, Novartis, GlaxoSmithKlein(GSK), UCB, AstraZeneca, AbbVie/Abbott, Boehringer-Ingelheim, Janssen, Pfizer; C. Weinert, None; M. Aringer, AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb(BMS), Eli Lilly, GlaxoSmithKlein(GSK), Merck/MSD, Novartis, Pfizer, Roche, Galapagos, Otsuka.

To cite this abstract in AMA style:

Leuchten N, Weinert C, Aringer M. In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/in-patients-with-rheumatoid-arthritis-clinical-examination-of-the-feet-is-important-for-understanding-individual-disease-burden-but-does-not-provoke-a-change-in-therapy-in-most-cases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-patients-with-rheumatoid-arthritis-clinical-examination-of-the-feet-is-important-for-understanding-individual-disease-burden-but-does-not-provoke-a-change-in-therapy-in-most-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology